Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 1, 1998, Pages 1-12

  DeNardo, Sally J ^a,c   Kroger, Linda A ^a   MacKenzie, Malcolm R ^b   Mirick, Gary R ^a   Shen, Sui ^a   DeNardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sacramento Medical Foundation Blood Center   (United States)

^c Molecular Cancer Institute   (United States)

Author keywords

Anti idiotype antibody; HAMA; Lym 1; Monoclonal antibody; Non Hodgkins lymphoma; Survival

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; HYDROXYUREA; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; NONHODGKIN LYMPHOMA; PLASMAPHERESIS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SURVIVAL TIME;

EID: 0031915457     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.1     Document Type: Article

References (45)

1. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko GM, Fisher LD, Porter B, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219.
2. Bernstein ID, Eary JF, Badger CC, Press OW, Appelbaurn FR, Martin PJ, Krohn KA, Nelp WB, Porter B, Fisher D, et al. High dose radiolabeled antibody therapy of lymphoma. Cancer Res 1990;50:1017.
3. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody J Clin Oncol 1991;9:548.
4. Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA. Phase 1 dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993;11:2021.
5. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al. Radioimmunotherapy of B-cell lymphoma with [1311] anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459.
6. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Lui CP, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 10:1696.
7. DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with 1311-Lym-1. Cancer Res 1990;50 Suppl:1014.
8. Eary JF. Radioimmunotherapy of B-cell lymphoma. Ann Oncol 1991;2:187
9. Lim SH, Marcus RE. Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas. Blood Rev 1992;6:157.
10. Larson SM, Macapinlac HA, Scott AM, Divgi CR. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncol 1993;32.709.
11. McMaster ML, Greer JP, Wolff SN, Johnson DH, Greco FA, Mize EM, Stein RS, Lousar JB, Jr., Flexner JM, Hainsworth JD. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma. Cancer 1991;68:233.
12. Shipp MA, Yeap BY, Harrington DP, Klatt MM, Pinkus GS, Jochelson MS, Rosenthal DS, Skarin AT, Canellos GP. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990;8:84.
13. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CAJ, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002.
14. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023.
15. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Lymphoma- selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996; 43:26.
16. Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen FM, Parker JW, Taylor CR. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830.
17. Kuzel T, Rosen ST, Zimmer AM, Silverstein EA, Spies S, Saletan SL, Norvitch ME, Birkhofer M, Shochat D, LoBuglio AF, et al. A phase 1 escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody Lym-1. Cancer Biother 1993;8:3.
18. Meredith R, Khazaeli MB, Plott G, Wheeler R, Russel C, Shochat D, Norvitch M, Saletan S, LoBuglio A Comparison of diagnostic and therapeutic doses of 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antibody Immunoconj Radiophar 1993;6:1.
19. Vriesendorp HM, Herpst JM, Germack MA, Klein JL, Leichner PK, Loudenslager DM, Order SE. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol 1991;9:918.
20. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991;9:478.
21. Parker BA, Vassos AB, Halpern SE, Miller RA, Hups H, Amox BG, Simoni JL, Starr RJ, Green MR, Royston L Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal antibody. Cancer Res 1990;50:1022.
22. DeNardo GL, DeNardo SJ. Treatment of B-lymphocyte malignancies with 131I-Lym-1 and 67Cu-2IT-BAT-Lym-1 and opportunities for improvement. In:Cancer Therapy with Radiolabeled Antibodies, Goldenberg DM(ed) CRC Press, Boca Raton, F1, 1994; 217.
23. DeNardo SJ, Peng J-S, DeNardo GL, Mills SL. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development Nucl Med Biol 1986;13:303.
24. DeNardo SJ, DeNardo GL, Peng JS. Pharmaceutical quality control of radiolabeled monoclonal antibodies and their fragments. Am J Physiol Imag 1989;4:39.
25. DeNardo GL, DeNardo SJ, Macey DJ, Mills SL. Quantitative phamacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In:Radiolabeled Monoclonal Antibodies for Imaging and Therapy, Srivastava SC(ed) Plenum Publishing Corp, New York, 1988; 293.
26. Snyder WS, Ford MR, Warner GG, Watson SB. "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. In:MIRD Pamphlet 11, Society for Nuclear Medicine, New York, 1975.
27. DeNardo SJ, O'Grady LF, Macey DJ, Kroger LA, DeNardo GL, Lamborn KR, Levy NB, Mills SL, Hellstrom I, Hellstrom KE. Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum [B] 1991;18:621.
28. DeNardo GL, Mirick GR, Kroger LA, O'Donnell RT, Meares CF, DeNardo SJ. Antibody responses to macrocycles in lymphoma. J Nucl Med 1996;37 451.
29. Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendorp HM, Bradley EW, Badger CC, Brill AB, Kwok CS, Stickney DR, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiophar 1990;3:213.
30. Macey DJ, DeNardo SJ, DeNardo GL, Goodnight JK, Unger MW Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma. Am J Physiol Imag 1988;3:1.
31. DeNardo GL, Lamborn KR, DeNardo SJ, Goldstein DS, Dolber-Smith EG, Kroger LA, Larkin EC, Shen S. Prognostic factors for radioimmunotherapy in patients with B-Lymphocytic malignancies. Cancer Res 1995; 55:5893.
32. DeNardo GL, Kroger LA, Mirick GR, Lamborn KR, DeNardo SJ Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocyte malignancies treated with 131I-Lym-1. Int J Biol Markers 1995; 10:67.
33. Lambom KR, DeNardo GL, DeNardo SJ, Goldstein DS, Larkin EC, and Kroger LA. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. Clin Cancer Res 1997;31253.
34. Baum RP, Neisen A, Hertel A, Hess H, Donnerstag B, Sykes T, Sykes C, Suresh M, Noujaim A, Hor G. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994; 1:73:1121.
35. Herlyn D, Ross AH, Koprowski H. Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 1986;232:100
36. Herlyn D, Zaloudik J, Somasundaram R, Jacob L, Benden A, Mastangelo M. Anti-idiotype vaccine in colorectal cancer patients. Hybridoma 1993;12:515.
37. Ferrone S.Human tumor-associated antigen mimicry by anti-idiotypic antibodies Immunogenicity and clinical trials in patients with solid tumors Ann N Y Acad Sci 1993;690:214.
38. Mittelman A, Chen ZJ, Kageshita T, Yang H, Yamada M, Baskind P, Goldberg N, Puccio C, Ahmed T, Arlin Z. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies [published erratum appears in J Clin Invest 1991 Feb;87(2):757]. J Clin Invest 1990;86:2136.
39. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 1994;54:415.
40. Mittelman A, Chen GZJ, Wong GY, Liu CC. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23-Modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1995;1:705.
41. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci 1992;89:466.
42. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974,125:373.
43. Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991;51: 5461.
44. Zimmer AM, Rosen ST, Spies SM, Goldman-Leikin R, Kazikiewicz JM, Silverstein EA, Kaplan EH. Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: Analysis of retreatment following plasmapheresis. J Nucl Med 1988;29.174.
45. Oldham RK. Regulatory hierarchies. Cancer Biother Radiophar 1997;12:137.